Asset 2 Conferences
Boutton Carlo - VIB Conferences

Carlo Boutton

Ablynx (Sanofi company), BE
Biography

Carlo Boutton obtained his PhD in 1999 at the University of Leuven (KUL - Belgium) on a subject that investigated the physico-chemical behavior of proteins under high-electromagnetic laser fields.

After his PhD he joined Algonomics (acquired by Lonza in 2009) where he contributed to the development of EpiBase: a platform to predict and identify T-cell epitopes in different biological modalities. In 2003 he joined Tibotec (a subsidiary of Johnson & Johnson) where he was involved in structure-based drug design of multiple anti-HIV and anti-HCV drug discovery projects.

Carlo started working with Nanobodies when he joined Ablynx in 2007. He initially set-up the bioinformatics and protein modelling team and became an expert in the sequence and structural aspects of such single domain antibodies. Gradually, he focused more on improvements of the NANOBODY platform and to the broadening of the Nanobody application scope to new therapeutic applications, including bispecifics, immunotherapeutics and Nanobody-drug-conjugates. After the acquisition of Ablynx by Sanofi in 2018, he continued focusing on innovation and currently holds the position of Global Head Innovation of the Large Molecules Research platform at Sanofi. In that role, he and his team are exploring novel technologies with Nanobodies, antibodies and other biologic modalities to find innovative solutions to today’s medical needs.

Speaker at